New therapies in the treatment of overactive bladder

Bibliography

• de Groat WC. A neurological basis for the overactive bladder. Urology 1997;50(6A Suppl):36-52
   PubMed Web of Science ®Google Scholar
• Brading AF. A myogenic basis for the overactive bladder. Urology 1997;50(6A Suppl):57-67
   PubMed Web of Science ®Google Scholar
• Drake MJ. The integrative physiology of the bladder. Ann R Coll Surg Engl 2007;89:580-5
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002;21(2):167-78
   PubMed Web of Science ®Google Scholar
• Abram P. Urgency: the key to defining the overactive bladder. BJU Int 2005;96:1-3
   Web of Science ®Google Scholar
• Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006;175(1):191-5
   PubMed Web of Science ®Google Scholar
• Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132-9
   PubMed Web of Science ®Google Scholar
• Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six western countries. BJU Int 2008;103:202-9
   Web of Science ®Google Scholar
• Abrams P, Cardozo L, Khoury S, Wein A. Incontinence. 5th International Consultation on Incontinence; Paris; 2012
   Google Scholar
• Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology 2006;68:318-23
   PubMed Web of Science ®Google Scholar
• Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OABq. Qual Life Res 2002;11:563-74
   PubMed Web of Science ®Google Scholar
• Matza LS, Thompson CL, Krasnow J, et al. Test–retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005;24:215-25
   PubMed Web of Science ®Google Scholar
• Shaw C, Matthews RJ, Perry SI, et al. Validity and reliability of an interviewer-administered questionnaire to measure the severity of lower urinary tract symptoms of storage abnormality: the Leicester Urinary Symptom Questionnaire. BJU Int 2002;90:205-15
   PubMed Web of Science ®Google Scholar
• Jackson S, Donovan J, Brookes S, et al. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. Br J Urol 1996;77:805-12
   PubMedGoogle Scholar
• Abrams P, Avery K, Gardener N, et al. The International Consultation on Incontinence Modular Questionnaire: www.iciq.net. J Urol 2006.175:1063-6
   Google Scholar
• Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-57; discussion 1564
   PubMed Web of Science ®Google Scholar
• Sarma AV, Kanaya A, Nyberg LM, et al. Risk factors for urinary incontinence among women with type 1 diabetes: findings from the epidemiology of diabetes interventions and complications study. Urology 2009;73(6):1203-9
   PubMed Web of Science ®Google Scholar
• Ramsay IN, Ali HM, Hunter M, et al. A randomized controlled trial of urodynamic investigations prior to conservative treatment of urinary incontinence in the female. Int Urogynecol J Pelvic Floor Dysfunct 1995;6(5):277-81
   Google Scholar
• Ward RM, Hampton BS, Blume JD, et al. The impact of multichannel urodynamics upon treatment recommendations for female urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2008;19(9):1235-41
   PubMed Web of Science ®Google Scholar
• Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs 2002;11(8):560-5
   PubMedGoogle Scholar
• Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol 2005;174(1):187-9
   PubMed Web of Science ®Google Scholar
• Greer JA, Smith AL, Arya LA. Pelvic floor muscle training for urgency urinary incontinence in women: a systematic review. Int Urogynecol J 2012;23(6):687-97
   Web of Science ®Google Scholar
• Yamanishi T. Efficacy of high-frequency continuous magnetic stimulator on urge incontinence [abstract MP-12.21]. Urology 2012;80(Suppl 3A):S125
   Google Scholar
• Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment for urinary incontinence in women. A Cochrane systematic review. Eur J Phys Rehabil Med 2008;44(1):47-63
   PubMed Web of Science ®Google Scholar
• Chess-Williams R, Chapple CR, Yamanishi T, et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auto Pharmacol 2001;21:243-8
   PubMedGoogle Scholar
• Fetscher C, Fleichman M, Schmidt M, et al. M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002;136:641-3
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100(5):987
   PubMed Web of Science ®Google Scholar
• Alhasso AA, McKinlay J, Patrick K, Steward L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006(4):CD003193
   Google Scholar
• Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006(4):CD003781
   Google Scholar
• Takeuchi T, Zaitsu M, Mikami K. Experience with imidafenacin in the management of overactive bladder disorder. Ther Adv Urol 2013;5(1):43-58
   Google Scholar
• Maggiore UL, Scala C, Venturini PL, Ferrero S. Imidafenacin for the treatment of overactive bladder. Expert Opin Pharmacother 2013;14(10):1383-97
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565-78
   PubMed Web of Science ®Google Scholar
• Brunger AT. Structure and function of SNARE and SNARE-interacting proteins. Q Rev Biophy 2005;38:1-47
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49(4):644-50
   PubMed Web of Science ®Google Scholar
• Moore KM, Hirst G, Emery S, et al. A double blind, placebo controlled, randomised, cross over study of trigone specific injections of botulinum toxin B for treating patients with idiopathic detrusor overactivity refractory to other conservative treatments [abstract number 209]. Neurourol Urodyn 2009;28(7):833-4
   Web of Science ®Google Scholar
• Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxin A for idiopathie detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 2011;30(7):1242-8
   PubMed Web of Science ®Google Scholar
• David G, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187(6):2131-9
   PubMed Web of Science ®Google Scholar
• Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006;68(5):993-7; 997-8
   PubMed Web of Science ®Google Scholar
• Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180(1):217-22
   PubMed Web of Science ®Google Scholar
• Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011(12):CD005493
   Google Scholar
• Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 2011;60(4):784-95
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184(6):2416-22
   PubMed Web of Science ®Google Scholar
• Malki M. OnabotulinumtoxinA (onabotA) 200 U vs 300 U: efficacy and safety in patients with DO [abstract 1970]. J Urol 2012;187(4 Suppl):e794
   Google Scholar
• Kuo HC. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity. Neurourol Urodyn 2011;30(8):1497-502
   PubMed Web of Science ®Google Scholar
• Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012;62(3):507-14
   PubMed Web of Science ®Google Scholar
• Schmid DM. BotulinumtoxinA (BTX-A): long-term impact in patients with OAB refractory to antimuscarinics [abstract 1972]. J Urol 2012;187(4 Suppl):e795
   PubMedGoogle Scholar
• Nitti V. Impact of onabotulinumtoxinA (onabotA) in patients with OAB and UI: phase III study results. Late-breaking news, AUA 2012
   Google Scholar
• Chapple C, Sievert KD, Macdiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Jiang Y-H. Impact of baseline urodynamic variables on short-term treatment outcome of onabotulinumtoxinA (onabotA) [abstract 2314]. J Urol 2012;187(4 Suppl):e934
   Google Scholar
• Finazzi-Agro E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol 2010;184(5):2001-6
   PubMed Web of Science ®Google Scholar
• Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol 2010;183(4):1438-43
   PubMed Web of Science ®Google Scholar
• Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009;182(3):1055-61
   PubMed Web of Science ®Google Scholar
• Peters K. Percutaneous tibial nerve stimulation (PTNS): long-term impact in patients with OAB [abstract 1177]. J Urol 2012;187(4 Suppl):e477
   PubMedGoogle Scholar
• Aggamy M. Posterior tibial nerve stimulation (PTNS) for treatment of refractory non-neurogenic DO and chronic pelvic pain syndrome (CPPS) [abstract .MP-12.03]. Urology 2012;80(Suppl 3A):S117-18
   Google Scholar
• National Institute for Health and Clinical Excellence NICE guidelines: posterior tibial nerve stimulation for overactive bladder syndrome. Available from: http://publications.nice.org/percutaneous-posterior-tibial-nerve=stimulation-for –overactive-bladder-syndrome-ipg362
   Google Scholar
• Chi T. Electrical vs magnetic stimulation of posterior tibial nerve (PTNS) [abstract 1651]. J Urol 2012;187(4 Suppl):e667
   Web of Science ®Google Scholar
• van Kerrebroeck PEV, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, Worldwide Clinical Study. J Urol 2007;178:2029-34
   PubMed Web of Science ®Google Scholar
• Peeters K. Sacral nerve stimulation (SNS): long-term efficacy in patients with voiding dysfunction [abstract 1956]. J Urol 2012;187(4 Suppl):e789
   PubMedGoogle Scholar
• Chang M. Sacral neuromodulation (SNM) failures [abstract MP-12.04]. Urology 2012;80(Suppl 3A):S118
   Google Scholar
• Kuss R, Bitker M, Camey M, et al. Indications and early and late results of intestinocystoplasty: a review of 185 cases. J Urol 1970;103:53-63
   PubMed Web of Science ®Google Scholar
• Greenwell TJ, Venn SN, Mundy AR. Augmentation cystoplasty. BJUI 2001;88:511-5257
   PubMed Web of Science ®Google Scholar
• McDougal WS. Metabolic complications of urinary intestinal diversion. J Urol 1992;147:1199-208
   PubMed Web of Science ®Google Scholar
• Smith P, Hardy GJ. Carcinoma occurring as a late complication of ileocystoplasty. BJU 1972;43:576-9
   Google Scholar
• Lane T, Shah J. Carcinoma following augmentation ileocystoplasty. Urol Int 2000;64(1):31-2
   PubMed Web of Science ®Google Scholar
• Asiam MZ, Agarwal M. Detrusor myomectomy. Long-term functional outcomes. Int J Urol 2012;19:1099-102
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Chapple CR. Beta3-adrenoceptors in Urinary Bladder. Neurourol Urodyn 2007;26(6):752-6
   PubMed Web of Science ®Google Scholar
• Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 2011;6(2):e16718
   PubMedGoogle Scholar
• Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50(2):317-26
   PubMed Web of Science ®Google Scholar
• Wesnes KA, Edgar C, Tretter RN, et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009;8(6):615-26
   PubMed Web of Science ®Google Scholar
• Wagg A. Treating overactive bladder in the elderly. Can Urol Assoc J 2011;5(5 Suppl2):S149-51
   PubMedGoogle Scholar
• DuBeau C. Individually titrated fesoterodine in vulnerable elderly patients with UUI: results from a double-blind RCT [abstract 1352]. J Urol 2012;187(4 Suppl):e548
   Google Scholar
• Weiss J. Impact of fesoterodine in patients with OAB including nocturnal urinary urgency [abstract 1963]. J Urol 2012;187(4 Suppl):e792
   PubMedGoogle Scholar
• Hampel C. Effect of flexible-dose solifenacin on cognition in geriatric patients with OAB [abstract POD-03.04]. Urology 2012;80(Suppl 3A):S10
   Google Scholar
• Hampel C. Efficacy and safety of flexible-dose solifenacin in men with OAB [abstract MP-12.17]. Urology 2012;80(Suppl 3A):S123-4
   Google Scholar
• Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder; a randomized controlled trial. JAMA 2006;296(19):2319-28
   PubMed Web of Science ®Google Scholar
• Athanasopoulos A, Chapple C, Fowler C, et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol 2011;60(5):994-1003
   PubMedGoogle Scholar
• McDonagh MS, Selover D, Santa J, et al. Drug class review. Agents for overactive bladder. Final report Update 4 Oregon Health & Science University, Oregon; Portland: 2009
   Google Scholar
• Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescrible antimuscarinic therapy for overactive bladder: a UK experience. BJUI 2012;110:1767-74
   PubMed Web of Science ®Google Scholar
• Lee YS, Choo MS, Lee JY, et al. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. Int J Clin Pract 2001;65(9):997-1004
   Google Scholar
• Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54(4):740-63
   PubMed Web of Science ®Google Scholar
• Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003;78(6):696
   PubMed Web of Science ®Google Scholar
• Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166(1):140
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168(2):580
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62(2):237
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005;23(4):263
   PubMed Web of Science ®Google Scholar
• Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur Urol 2007;51(4):907
   PubMed Web of Science ®Google Scholar
• Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 2009;10(18):3103-11
   PubMed Web of Science ®Google Scholar
• Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009;181(4):1764-72
   PubMed Web of Science ®Google Scholar
• Sand PK, Davila GW, Lucente VR, et al. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol 2012;206(2):168.e1-6
   PubMed Web of Science ®Google Scholar
• Goldfischer E. Efficacy and safety of oxybutynin topical gel (OTG): results from a multi-centre RCT [abstract 522]. J Urol 2012;187(4 Suppl):e214
   Google Scholar
• ClinicalTrials.gov, 17 Jun 2008 & 22 Mar 2010, NCT00685113
   Google Scholar
• Lucas MG, Bosch RJL, Burkhard FC, et al. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. Eur Urol 2012;62:1130-42
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00409539
   Google Scholar
• ClinicalTrials.gov. 2011. Available from: http://clinicaltrials.gov/show/NCT01458197
   Google Scholar
• Press release, SALVAT. 2010. Available from: http://pharmalive.com/News/index.cfm?articleid=745187&categoryid=21
   Google Scholar
• Khullar V. Effect of mirabegron on OAB: patient-reported outcomes [abstract MP-12.16]. Urology 2012;80(Suppl 3A):S123
   Google Scholar
• Urodynamic safety of mirabegron in men with LUTS and BOO: results from a phase II study <Nitti V [abstract 1869]. J Urol 2012;187(4 Suppl):e756
   Google Scholar
• Yamaguchi O. Outcome of mirabegron treatment in Japanese patients with OAB [abstract POD-03.06]. Urology 2012;80(Suppl 3A):S10-1
   Google Scholar
• Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the beta3-Adrenoceptor agonist solabegron for overactive bladder. Eur Urol 2012;62(5):834-40
   PubMed Web of Science ®Google Scholar
• Michel M. β3-AR agonist solabegron: impact in women with OAB [abstract 520]. J Urol 2012;187(4 Suppl):e213
   PubMedGoogle Scholar
• Hougaard C, Fraser MO, Chien C, et al. A positive modulator of K Ca 2 and K Ca 3 channels, 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591), inhibits bladder afferent firing in vitro and bladder overactivity in vivo. J Pharmacol Exp Ther 2009;328:28-39
   PubMed Web of Science ®Google Scholar
• Darblade B, Behr-Roussel D, Oger S, et al. Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder. Urology 2006;68:442-8
   PubMed Web of Science ®Google Scholar
• Shieh C-C, Brune ME, Buckner SA, et al. Characterization of a novel ATP-sensitive K+ channel opener, A-251179, on urinary bladder relaxation and cystometric parameters. Br J Pharmacol 2007;151:467
   PubMed Web of Science ®Google Scholar
• Chapple CR, Patroneva A, Raines SR. Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). Eur Urol 2006;49:879
   Web of Science ®Google Scholar
• Juszczak K, Ziomber A, Thor PJ. Effect of partial and complete blockade of vanilloid (TRPV1-6) and ankyrin (TRPA1) transient receptor potential ion channels on urinary bladder motor activity in an experimental hyperosmolar overactive bladder rat model. J Physiol Pharmacol 2011;62:321-6
   PubMed Web of Science ®Google Scholar
• Liu HZ, Kuo HC. Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity. BJUI 2007;100:1086-90
   PubMed Web of Science ®Google Scholar
• Kuo HC. Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics. BJUI 2005;95:1023-7
   PubMed Web of Science ®Google Scholar
• Maggi CA, Barbanti G, Santicioli P, et al. Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. J Urol 1989;142:150-4
   PubMed Web of Science ®Google Scholar
• Truss MC, Stief CG, Uckert S, et al. Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 2000;18:439
   PubMed Web of Science ®Google Scholar
• Francois A, et al. A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. BJUI 2010;106:666-73
   PubMed Web of Science ®Google Scholar
• Oger S, Behr-Roussel D, Gorny D, et al. Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol 2010;160:1135-43
   PubMed Web of Science ®Google Scholar
• Behr-Roussel D, Oger S, Caisey S, et al. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol 2010;59:272-9
   PubMed Web of Science ®Google Scholar
• Stief CG, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to BPH. Eur Urol 2008;53:1236-44
   PubMed Web of Science ®Google Scholar
• Martinez-Salamanca JI, Carballido J, Eqidley I, et al. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms. Critical analysis of current evidence. Eur Urol 2011;60:527-35
   PubMed Web of Science ®Google Scholar
• Cardozo LD, Stanton SL, Robinson H, et al. Evaluation on flurbiprofen in detrusor instability. Br Med J 1980;280:281
   PubMed Web of Science ®Google Scholar
• Tyagi V, Philips BJ, Su R, et al. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 2009;181:1932-8
   PubMed Web of Science ®Google Scholar
• Freeman RM, Adekanmi O, Waterfield MR, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomized placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17:636-41
   PubMed Web of Science ®Google Scholar
• Covenas R, Martin F, Belda M, et al. Mapping of neurokinin-like immunoreactivity in the human brainstem. BMC Neurosci 2003;4(1):3
   PubMedGoogle Scholar
• Quinn T, Collins C, Baird AW. Mechanisms of neurokinin A- and substance P-induced contractions in rat detrusor smooth muscle in vitro. BJU Int 2004;94:651-7
   PubMed Web of Science ®Google Scholar
• Green SA, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006;176(6 Pt 1):2535
   PubMed Web of Science ®Google Scholar
• Frenkl TL, Zhu H, Reiss T, et al. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol 2010;184(2):616-22
   PubMed Web of Science ®Google Scholar
• Hunsballe JM, Djurhuus JC. Clinical option for imipramine in the management of urinary incontinence. Urol Res 2001;29:118-25
   PubMed Web of Science ®Google Scholar
• Lose G, Jorgensen L, Thunedborg P. Doxepin in the treatment of female detrusor overactivity; a randomized double-blind crossover study. J Urol 1989;142:1024-6
   PubMed Web of Science ®Google Scholar
• Steers WD, Herchorn S, Kreder KJ, et al. Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive baldder. BJU Int 2007;100(2):337-45
   PubMed Web of Science ®Google Scholar
• Nagasaka Y, Yokoyama O, Komatsu K, et al. Effects of opioid subtypes on detrusor overactivity in rats with cerebral infarction. Int J Urol 2007;14(3):226-31; discussion 232
   PubMed Web of Science ®Google Scholar
• Andersson KE, Wien AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004;56(4):581-631
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study. Br J Clin Pharmacol 2006;61(4):456-63
   PubMed Web of Science ®Google Scholar
• Pehrson R, Andersson KE. Effects of tiagabine, a gammaaminobutyricacid re-uptake inhibitor, on normal rat bladder function. J Urol 2002;167:2241-6
   PubMed Web of Science ®Google Scholar
• Kim YT, Kwon DD, Kim J, et al. Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int Braz J Urol 2004;30:275-8
   PubMedGoogle Scholar
• Khullar V, Cambronero J, Stroberg P, et al. The efficacy and tolerability of mirabegron in patients with overactive bladder – results from a European-Australian Phase III trial. Presented at the 26th Annual Congress of the European Association of Urology; 18-22 March 2011; Vienna, Austria
   Google Scholar
• Nitti V, Herschorn S, Auerbach S, et al. The efficacy and safety of mirabegron in patients with overactive bladder syndrome – results from a North-American Phase III trial. Presented at the 26th Annual Congress of the European Association of Urology; 18-22 March 2011; Vienna, Austria
   Google Scholar
• A 12wk randomized, double-blind, parallel-group, placebo-controlled, multicentre Phase III trial (178-CL-074, 2008-007087-42) in Canada, Czeh Republic, Denmark, Finland, Germany, Hungary, Norway, Slovalia, Spain, Sweden and the US, to assess the efficacy and safety of the mirabegron once-daily modified-release tablet. ClinicalTrials.gov. 2010 & 2011. Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT00912964
   Google Scholar
• A phase III trial 2452 patients with OAB (TAURUS) in Australia, Austria, Belarus, Belgium, Canada, Czeh Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Italy, Latvia, Lithuania, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, S Africa, Spain, Sweden, Switzerland, Ukraine, the UK and the US. ClinicalTrials.gov. 2010. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00688688
   Google Scholar